换一批
换一批Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
作者：
主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 单克隆(Antibodies, Monoclonal);抗体, 肿瘤(Antibodies, Neoplasm);无病生存(Disease-Free Survival);用药计划表(Drug Administration Schedule);女(雌)性(Female);血液病(Hematologic Diseases);人类(Humans);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);男(雄)性(Male);中年人(Middle Aged);机会致病菌感染(Opportunistic Infections);缓解诱导(Remission Induction);挽救疗法(Salvage Therapy);存活率分析(Survival Analysis)
DOI
10.1080/10428190310001615675
PMID
15160944
发布时间
2019-01-16
- 浏览29
Leukemia & lymphoma
711-4页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
